Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DONOR CARD

Financiado

Cerrado

Development of a Nitric Oxide Releasing Stent for Treatment of Coronary Artery D...

Development of a Nitric Oxide Releasing Stent for Treatment of Coronary Artery Disease Coronary artery disease is one of the leading causes of death worldwide. Significant advances in treating coronary artery disease have been made over the last decade with the introduction of percutaneous coronary intervention (PCI... ver más

30/11/2014

BSUHT

986K€

Presupuesto del proyecto: 986K€

Líder del proyecto

BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-11-30 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

BSUHT

0.00€ | Lider

UNIVERSITY OF BRIGHTON

N.D. | Participante

Hexacath

428.71K€ | Participante

Proyectos interesantes

BIOMAGSCAR

Medical Technol...

Materials Scien...

7M€ Cerrado

PID2021-124868OB-C22

Medical Technol...

Materials Scien...

94K€ Cerrado

REBIOSTENT

Medical Technol...

Materials Scien...

6M€ Cerrado

DESARROLLO DE STENTS CARDIOVASCULARES CON CAP...

Medical Technol...

Materials Scien...

20K€ Cerrado

EPICSTENT

Medical Technol...

Materials Scien...

1M€ Cerrado

HEART PATCH

Medical Technol...

Materials Scien...

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 986K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Coronary artery disease is one of the leading causes of death worldwide. Significant advances in treating coronary artery disease have been made over the last decade with the introduction of percutaneous coronary intervention (PCI). PCI involves the placement of stents within narrowed arteries relieving the symptoms of angina and in some cases increasing life expectancy. The two major problems with currently available stent designs are restenosis and late thrombosis. The former is more common in uncoated stents and was addressed with the introduction of drug releasing stents. However, concerns have been raised about the increased incidence of stent thrombosis with these drug releasing stents. An innovative design of stent utilising titanium oxynitride (Titan 2) was the first of the bioactive stents which compared favourably in efficacy to the drug coated stents but with less re-narrowing than with the uncoated stents. The Titan 2 uses the fundamental biocompatibility of titanium to reduce inflammation and promote healing after stenting. Nitrous oxide (NO) is an important regulator of endothelial cell function. We will design a bioactive titanium oxynitride coated stent which will release NO after stent implantation. It is proposed that this will have beneficial effects to endothelial function after stenting and possibly reduce the incidence of re-narrowing and stent thrombosis. The new metal stent will be tested in vitro using primary human monocytes and platelets and using a human derived endothelial cell line. We aim to achieve excellent biomaterial properties as applied to coronary artery stenting, a highly biocompatible surface and to demonstrate release of NO after stent deployment. To achieve this we will combine the knowledge of our industrial, medical and scientific partners to develop a new coronary stent which will be of significant benefit to patients with coronary artery disease both in the European Union and worldwide.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores